Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Puma Biotechnology Inc (NASDAQ:PBYI) by 141.6% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,559 shares of the biopharmaceutical company’s stock after buying an additional 1,500 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Puma Biotechnology were worth $306,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently added to or reduced their stakes in PBYI. New York State Common Retirement Fund grew its stake in shares of Puma Biotechnology by 4.7% in the 2nd quarter. New York State Common Retirement Fund now owns 32,247 shares of the biopharmaceutical company’s stock worth $2,818,000 after purchasing an additional 1,446 shares during the last quarter. Teacher Retirement System of Texas acquired a new position in shares of Puma Biotechnology in the 2nd quarter worth approximately $211,000. BlackRock Inc. grew its stake in shares of Puma Biotechnology by 5.0% in the 2nd quarter. BlackRock Inc. now owns 1,830,342 shares of the biopharmaceutical company’s stock worth $159,973,000 after purchasing an additional 86,924 shares during the last quarter. Prudential Financial Inc. acquired a new position in shares of Puma Biotechnology in the 2nd quarter worth approximately $302,000. Finally, Alliancebernstein L.P. grew its stake in shares of Puma Biotechnology by 5.1% in the 2nd quarter. Alliancebernstein L.P. now owns 41,140 shares of the biopharmaceutical company’s stock worth $3,596,000 after purchasing an additional 2,000 shares during the last quarter. Institutional investors own 96.05% of the company’s stock.

Puma Biotechnology Inc (NASDAQ PBYI) opened at $93.85 on Wednesday. Puma Biotechnology Inc has a 1 year low of $28.35 and a 1 year high of $136.90.

Puma Biotechnology (NASDAQ:PBYI) last released its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($2.07) earnings per share for the quarter, topping the consensus estimate of ($2.50) by $0.43. The firm had revenue of $6.10 million during the quarter, compared to analysts’ expectations of $3.78 million. During the same period last year, the business earned ($1.11) earnings per share. sell-side analysts predict that Puma Biotechnology Inc will post -8.19 earnings per share for the current fiscal year.

Several equities analysts have recently issued reports on the stock. BidaskClub cut shares of Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, November 14th. Credit Suisse Group lifted their price objective on shares of Puma Biotechnology from $136.00 to $142.00 and gave the stock an “outperform” rating in a research note on Friday, November 10th. Barclays reaffirmed a “buy” rating and issued a $122.00 price objective (up previously from $103.00) on shares of Puma Biotechnology in a research note on Friday, November 10th. Citigroup lifted their price objective on shares of Puma Biotechnology from $156.00 to $164.00 and gave the stock a “buy” rating in a research note on Friday, November 10th. Finally, Royal Bank Of Canada lowered their price objective on shares of Puma Biotechnology from $108.00 to $92.00 and set a “sector perform” rating on the stock in a research note on Friday, November 10th. They noted that the move was a valuation call. One investment analyst has rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company’s stock. Puma Biotechnology currently has a consensus rating of “Buy” and a consensus price target of $130.67.

In related news, SVP Richard Paul Bryce sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, September 29th. The shares were sold at an average price of $120.00, for a total transaction of $1,800,000.00. Following the completion of the sale, the senior vice president now directly owns 42,239 shares in the company, valued at $5,068,680. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Charles R. Eyler sold 1,322 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $105.46, for a total transaction of $139,418.12. The disclosure for this sale can be found here. Over the last three months, insiders sold 31,322 shares of company stock worth $3,440,768. 21.10% of the stock is currently owned by insiders.

TRADEMARK VIOLATION NOTICE: This article was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.thecerbatgem.com/2017/12/06/puma-biotechnology-inc-pbyi-holdings-increased-by-zurcher-kantonalbank-zurich-cantonalbank.html.

Puma Biotechnology Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Institutional Ownership by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Stock Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related stocks with our FREE daily email newsletter.